Feedback
Settings

Settings

Goto Application

2,481 results
Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC_EX:A61K39/44

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 249
1.WO/2020/103910POLYPEPTIDE FOR TREATING PATHOLOGICAL BLOOD CLOTS
WO - 28.05.2020
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
 Appl.No PCT/CN2019/120004 Applicant IMMUNWORK INC. Inventor CHANG, Tse-Wen
The present disclosure provides a polypeptide including an anti-fibrin antibody and a serine protease moiety of human tissue plasminogen activator. Methods for treating thrombosis in a subject in need of such treatment using such polypeptide are also disclosed.
2.WO/2020/102609COMPOSITIONS AND METHODS FOR THE CYTOPLASMIC DELIVERY OF ANTIBODIES AND OTHER PROTEINS
WO - 22.05.2020
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
 Appl.No PCT/US2019/061575 Applicant THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Inventor TSOURKAS, Andrew
The invention provides compositions and methods for the cytoplasmic delivery of antibodies and other proteins. Specifically, provided herein are compositions having an anionic polypeptide and a cationic transfection agent for facilitating the cytoplasmic delivery of an antibody or a protein.
3.WO/2020/097139CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
WO - 14.05.2020
Int.Class A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
 Appl.No PCT/US2019/059954 Applicant MERCK SHARP & DOHME CORP. Inventor ANTOCHSHUK, Valentyn
The present invention provides co-formulations of anti-PD-1 antibodies and anti-LAG3 antibodies, and their use in treating various disorders.
4.3650038IN VIVO TARGETING OF CELLS WITH LIGAND-CONJUGATED PARTICLES
EP - 13.05.2020
Int.Class A61K 38/20
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
20Interleukins
 Appl.No 19189418 Applicant MASSACHUSETTS INST TECHNOLOGY Inventor IRVINE DARRELL J
The invention provides compositions and methods for,inter alia,augmenting cell-based therapiesin vivoby repeatedly stimulating target cells of interest over a period of time.
5.111018986抗磷脂酰肌醇蛋白多糖-3的抗体及其应用
CN - 17.04.2020
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No 201910736574.8 Applicant 科济生物医药（上海）有限公司 Inventor 王华茂
本发明涉及抗磷脂酰肌醇蛋白多糖‑3(GPC3)的抗体及其应用。本发明揭示了新的特异性识别GPC3的抗体。本发明的抗体可以被应用于制备靶向性抗肿瘤药物以及诊断肿瘤的药物。
6.WO/2020/076849ANTIBODY COMPOUNDS WITH REACTIVE ARGININE AND RELATED ANTIBODY DRUG CONJUGATES
WO - 16.04.2020
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
 Appl.No PCT/US2019/055224 Applicant THE SCRIPPS RESEARCH INSTITUTE Inventor RADER, Christoph
The present invention provides antibody compounds that contain a substitution of arginine for the reactive lysine residue (Lys99) in the hydrophobic cleft (38C2_Arg). The invention also provides antibody drug conjugate compounds (ADCs) that contain cargo moieties that are site-specifically conjugated to the engineered arginine residue in the 38C2_Arg variant antibody. Further provided in the invention are therapeutic applications of the compounds.
7.WO/2020/070288METHODS AND SYSTEMS FOR CONTROLLING THE AGONISTIC PROPERTIES OF ANTIBODY VARIABLE DOMAINS BY LIGHT
WO - 09.04.2020
Int.Class A61K 39/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
44Antibodies bound to carriers
 Appl.No PCT/EP2019/076914 Applicant INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) Inventor LASSERRE, Rémi
The inventors has developed a recombinant molecular system, named OptoFab, allowing the accurate control of the agonistic properties of an antibody-derived Fab fragment in time and in space using specific wavelengths of light. It consists in a Fab fragment derived from an agonistic antibody of interest, linked to optogenetic modules that confer a light response capacity. Indeed, antibody derived Fab fragments generally keep the specificity of the antibody for its epitope, but not its agonistic properties. However, when Fab fragments are oligomerized, they recover the agonistic properties of the whole antibody. These characteristics, are at the basis of the OptoFab concept as its objective is to manipulate the oligomerization/immobilization statue of a Fab fragment using optogenetics to control its agonistic property. The present invention relates to methods and systems for controlling the agonistic properties of antibody variable domains by light.
8.20200095546NANOSCALE ARTIFICIAL ANTIGEN PRESENTING CELLS
US - 26.03.2020
Int.Class C12N 5/0781
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
078Cells from blood or from the immune system
0781B cells; Progenitors thereof
 Appl.No 16548953 Applicant The Johns Hopkins University Inventor Jonathan Schneck

This disclosure provides nano-scale Artificial Antigen Presenting Cells (aAPC), which deliver stimulatory signals to lymphocytes, including cytotoxic lymphocytes, for use as a powerful tool for immunotherapy.

9.3626743ANTI-CD83 ANTIBODIES AND USE THEREOF
EP - 25.03.2020
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No 19203675 Applicant KIRA BIOTECH PTY LTD Inventor SELDON THERESE ANN
The present disclosure relates to proteins that bind to CD83 and uses thereof, for example, in therapy, prophylaxis, diagnosis, or prognosis.
10.WO/2020/055932METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING A GM-CSF ANTAGONIST
WO - 19.03.2020
Int.Class A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
 Appl.No PCT/US2019/050494 Applicant HUMANIGEN, INC. Inventor DURRANT, Cameron
Methods for neutralizing and/or removing human GM-CSF in a subject in need thereof, comprising administering to the subject CAR-T cells having a GM-CSF gene knockout (GM-CSFk/o CAR-T cells) are provided. Also provided are methods for GM-CSF gene inactivation or GM-CSF knockout (KO) in a cell comprising targeted genome editing or GM-CSF gene silencing. Methods for preventing/treating immunotherapy-related toxicity, comprising administering to the subject CAR-T cells having a GM-CSF gene inactivation or GM-CSF knockout (GM-CSFk/o CAR-T cells), wherein the GM-CSF gene is inactivated or knocked out and/or a recombinant GM-CSF antagonist are provided. Methods for reducing a level of a cytokine or chemokine other than GM-CSF in a subject having immunotherapy-related toxicity comprising administering to the subject a recombinant hGM-CSF antagonist are provided. Also provided are methods for treating or preventing immunotherapy-related toxicity in a subject, comprising administering to the subject chimeric antigen receptor-expressing T-cells (CAR-T cells), the CAR-T cells having a GM-CSF gene knockout (GM-CSFk/o CAR-T cells). Methods for preventing or reducing blood-brain barrier disruption in a subject treated with immunotherapy, the method comprising administering CAR-T cells having a GM-CSF gene knockout (GM-CSFk/o CAR-T cells) to the subject, also are provided.
# -